FDA gives ViiV AIDS drug priority review
An AIDS drug being developed by ViiV Healthcare will get speedier review from the Food and Drug Administration. A regulatory decision is scheduled for Aug. 17 after ViiV submitted an application on Dec. 17, the London-based company said in a statement today. The FDA gave dolutegravir priority review status, which is granted to drugs that have the potential to offer significant improvement over existing therapies or where no adequate treatment exists, the company said. ViiV, is a joint venture comprised of three drug firms: GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and Japan’s Shionogi. ViiV maintains its U.S. headquarters at GSK’s campus...
Read More
